How to Buy Beam Therapeutics Inc. Common Stock (BEAM) Stock

Where to buy BEAM

13 brokers in our matrix offer BEAM. Verify availability and current fees with each broker before trading.

Broker	Commission	Fractional	Extended	Overnight	Options	OTC access
Charles Schwab (thinkorswim)Review	$0	Schwab Stock Slices, S&P 500 only, ≥ $5/slice, up to 30 at once		~1,130	$0.65	Most (3/5)
E*TRADE (Morgan Stanley)Review	$0 listed			~20	$0.65	Most (4/5)
FidelityReview	$0	Stocks by the Slice, 7,000+ stocks/ETFs, from $1			$0.65	Partial (2+0)
FirstradeReview	$0	~4,000+ tickers, ≥ $5		~1,200	$0	Most (4/5)
Interactive BrokersReview	$0 (Lite) / per-share (Pro)			~10,000	per-contract pricing	Full
Merrill EdgeReview	$0				$0.65	Most (3/5)
MoomooReview	$0				$0	Limited only
Public.comReview	$0				rebate model	Limited only
RobinhoodReview	$0	≥ $1 stocks, market cap ≥ $25M		~1,134	$0	None
SoFi Active InvestingReview	$0				$0	Partial (1+2)
tastytradeReview	$0 stocks				$1.00 open, $0 close (capped at $10 per leg)	Limited only
TradeStationReview	$0 listed				$0.50 / $0.60	Most (4/5)
WebullReview	$0				$0	Limited only

24-Hour / Overnight trading

BEAM may be eligible for overnight trading via Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), Webull, Moomoo, Firstrade. Each broker maintains its own eligibility list — confirm before placing an order.

About Beam Therapeutics Inc. Common Stock

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Employees

522

Headquarters

CAMBRIDGE, MA

Listed

2020-02-06

Market cap

$2.79B

Frequently asked

Where can I buy Beam Therapeutics Inc. Common Stock (BEAM)?

BEAM is offered by 13 brokers in our matrix, including Charles Schwab (thinkorswim), E*TRADE (Morgan Stanley), Fidelity, Firstrade, Interactive Brokers. Compare commissions, fractional eligibility, and overnight availability in the broker matrix above.

Can I buy BEAM after hours or overnight?

Yes. BEAM is on the 24-hour eligibility list for Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), and others. Overnight sessions route through ATSs with wider spreads and limit-orders only.

Does Robinhood offer BEAM?

Yes. Robinhood offers BEAM as a regular exchange-listed security.

Does Fidelity offer BEAM?

Yes. Fidelity offers BEAM as a regular exchange-listed security.

Does Webull offer BEAM?

Yes. Webull offers BEAM as a regular exchange-listed security.

Is BEAM optionable?

Yes. BEAM has listed options contracts. Per-contract pricing varies by broker — see the Options column in the matrix.

Is there a tokenized version of BEAM?

Not in our current dataset. The tokenized stock universe (Kraken xStocks, Binance Alpha/Ondo, Robinhood EU, Hyperliquid HIP-3) is expanding quickly — we refresh quarterly.

Can I buy a fractional share of BEAM?

Yes. Multiple brokers in the matrix support fractional shares for BEAM — see the Fractional column above for per-broker eligibility and minimums.